only back to pre cr diluted levels.
2-3c is fair. 4-5c strectched and 5c+ overvalued.
all just opinion of course.
If they show some more real progress then we have a clear year or 2 without the risk of a CR and if they bagged a grant out of cancerUK in 2016 then 10c+ because of validation from scientific peers and overfunded.
In the meantime we will have to live with the cheer squad, the armchair scientists and the various level of liquid in our respective glasses.
Andrew65 and Bioexec - if you haven't asked your questions directly of the company then I have little more to say here - you remain as helpful as the rest of us.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |